神經退化性疾病市場：按適應症、藥物類型和地區分類 -

預計到 2026 年，神經退化性疾病治療市場規模將達到 466.531 億美元，到 2033 年將達到 588.757 億美元。預計 2026 年至 2033 年的複合年成長率為 3.4%。

神經退化性疾病是指中樞神經系統細胞功能喪失或死亡的一類疾病。神經退化性疾病是由神經元結構和功能逐漸喪失所引起的，這個過程稱為神經退化。阿茲海默症和帕金森氏症是最常見的神經退化性疾病。神經退化性疾病通常會隨著時間推移而惡化，目前尚無治癒方法。

市場動態：

神經退化性疾病的日益普及、老年人口的增加、對安全有效療法的需求不斷成長、公眾對神經退化性疾病和現有療法的認知不斷提高，以及強大的產品平臺，預計這些因素將推動全球神經退化性疾病市場在預測期內的成長。

例如，2022 年 10 月，Cyclo Therapeutics 宣布啟動 Trappsol Cyclo 的 2b 期臨床試驗，Trappsol Cyclo 是一種臨床實驗藥物，旨在減少澱粉樣蛋白BETA和Tau ，用於治療早期阿茲海默症。

此外，2022 年 8 月，Amneal Pharmaceuticals 向美國食品藥物管理局(FDA) 提交了 IPX203 的新藥認證申請，IPX203 是一種新型的碳度巴/左旋多巴緩釋膠囊口服製劑，用於治療帕金森氏症。

本研究的主要特點：

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據公司概況、產品系列、主要亮點、財務績效和策略等參數，介紹了全球神經退化性疾病市場主要公司的概況。
• 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份全球神經退化性疾病市場報告的目標對象包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等行業相關人員相關者。
• 相關人員可以透過利用分析全球神經退化性疾病市場中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 神經退化性疾病盛行率增加
  • 嚴格的監管準則
  • 對新型治療藥物的需求增加
• 影響分析
• 主要亮點
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景

第4章 全球神經退化性疾病市場：依適應症類型分類，2021-2033年

• 帕金森氏症
• 阿茲海默症
• 多發性硬化症
• 亨丁頓舞蹈症
• 其他適應症類型

第5章 全球神經退化性疾病市場：依藥物類型分類，2021-2033年

• N-甲基-D-天門冬胺酸受體拮抗劑
• 膽鹼酯酶抑制劑
• 多巴胺促效劑
• 免疫調節藥物
• 其他藥物類型

第6章 全球神經退化性疾病市場：依地區分類，2021-2033年

• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東和非洲
• 世界其他地區

第7章 競爭情勢

• Abbvie Inc.
• Amneal Pharmaceuticals Inc.
• Boehringer Ingelheim International Gmbh
• F. Hoffmann-La Roche
• Merck & Co. Inc.

第8章

• 調查方法
• 關於本公司

Neurodegenerative Disease Treatment Market is estimated to be valued at USD 46,653.1 Mn in 2026 and is expected to reach USD 58,875.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.4% from 2026 to 2033.

Neurodegenerative disease is a type of disease in which cells of the central nervous system stop working or die. Neurodegenerative disease is caused by the progressive loss of structure or function of neurons, in a process known as neurodegeneration. Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases. Neurodegenerative disorders usually get worse over time and have no cure.

Market Dynamics:

Rise in prevalence of neurodegenerative diseases, growing geriatric population, rise in demand for safe and effective therapeutics, increasing public awareness about neurodegenerative disease and available therapeutics, and strong product pipeline are major factors expected to propel growth of the global neurodegenerative disease market over the forecast period.

For instance, in October 2022, Cyclo Therapeutics announced the launch of a Phase 2b study for its investigational drug, named Trappsol Cyclo, which targets the reduction of amyloid beta and tau to treat early Alzheimer's disease.

Moreover, in August 2022, Amneal Pharmaceuticals submitted a New Drug Application to the Food & Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson's disease.

Key Features of the Study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global neurodegenerative disease market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Amneal Pharmaceuticals Inc., Boehringer Ingelheim International Gmbh, F. Hoffmann-La Roche, Abbvie Inc., and Merck & Co. Inc., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global neurodegenerative disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurodegenerative disease market.

Detailed Segmentation:

• Global Neurodegenerative Disease Market, By Indication Type (Revenue, USD Mn, 2021 - 2033)
• Parkinson's Disease
• Alzheimer's Disease
• Multiple Sclerosis
• Huntington Disease
• Other Indication Types
• Global Neurodegenerative Disease Market, By Drug Type (Revenue, USD Mn, 2021 - 2033)
• N-methyl-D-aspartate Receptor antagonists
• Cholinesterase Inhibitors
• Dopamine Agonists
• Immunomodulatory Drugs
• Other Drug Types
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles:
• Abbvie Inc.
• Amneal Pharmaceuticals Inc.
• Boehringer Ingelheim International Gmbh
• Hoffmann-La Roche
• Merck & Co. Inc.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Indication Type
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in prevalence of neurodegenerative diseases
  • Stringent regulatory guidelines
  • Increase in demand for novel therapeutics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Neurodegenerative Disease Market, By Indication Type, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Parkinson's Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Alzheimer's Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Multiple Sclerosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Huntington Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Other Indication Types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

5. Global Neurodegenerative Disease Market, By Drug Type, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• N-methyl-D-aspartate Receptor Antagonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Cholinesterase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Dopamine Agonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Immunomodulatory Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Other Drug Types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

6. Global Neurodegenerative Disease Market, By Geography, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
• Rest of World
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)

7. Competitive Landscape

• Abbvie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amneal Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim International Gmbh
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-La Roche
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co. Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

8. Section

• Research Methodology
• About us